Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) fell 5.5% during trading on Monday . The stock traded as low as $8.05 and last traded at $8.05, with a volume of 180,801 shares traded. The stock had previously closed at $8.52.

Several research firms recently commented on FOMX. Zacks Investment Research downgraded Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of Foamix Pharmaceuticals in a report on Tuesday, May 10th.

The firm’s market capitalization is $249.02 million. The company has a 50 day moving average of $6.71 and a 200-day moving average of $6.54.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.08. Analysts predict that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current fiscal year.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.